ja_mageia

Neurofibromatosis type 2: the state of the art
Organizers: D. Brackmann, M. Giovannini, B. Shannon
Las Vegas, May 3-4, 2010

Sunday May 2, 2010

Monday May 3, 2010

7:45AM – 10:15AM: Session 1 – NF2 research: From bench to bedside
Chairmen: M. Giovannini and A. Stemmer-Rachamimov

7:45AM-8:00AM                 Welcome Address

8:00AM-8:20AM                 Genetics of NF2
                                             Gareth Evans MD (University of Manchester, Manchester, UK)

8:20AM-9:20AM                 Mechanisms of NF2 tumor suppression
                                             Andrea McClatchey PhD (Massachusetts General Hospital, Boston, MA, USA)
                                             Helen Morrison PhD (Leibniz Institute for Age Research, Jena, Germany)
                                             Filippo Giancotti MD, PhD (Memorial Sloan Kettering Cancer Center, New York, NY, USA)

9:20AM – 9:40AM               Familial schwannomatosis
                                             Theo Hulsebos PhD (Academic Medical Center, Amsterdam, The Netherlands)

9:40AM – 10:00AM             Pathology of NF2 tumors
                                             Anat Stemmer-Rachamimov MD (Massachusetts General Hospital, Boston, MA, USA)

10:00AM - 10:20AM           Coffee Break                   

10:20AM–10:40AM             Talks selected from abstracts

10:20AM-10:30AM              Phosphoinositide binding of the FERM domain of merlin regulates its membrane raft association,
                                             subcellular dynamics and function - Platform Abstract Presentation
                                             Timmy Mani (University of Cincinnati, Cincinnati, OH, USA) 

10:40AM–1:00PM: Session 2 - NF2 tumor management: towards the end of the preconceived ideas (Part 1)
Chairmen: D. Brackmann and John Golfinos

10:40AM-11:00AM            Natural History of NF2
                                            William Slattery MD (House Ear Institute, Los Angeles, CA, USA)

11:00AM-11:20AM            Timing in NF2 Tumor Treatment: Which, When, Why?
                                            Michel Kalamarides MD, PhD (Hôpital Beaujon, Paris, France)

11:20AM-11:40AM            Meningioma: a crucial tumor in NF2
                                           John Golfinos, MD (New York University, New York, NY, USA)

11:40AM-12:00PM            Trans-labyrinthine approach for NF2-vestibular schwannoma
                                            David Moffat, MD (Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK)

12:00PM-12:20PM             Middle fossa approach for NF2 vestibular schwannoma
                                            Derald Brackmann, MD (House Ear Institute, Los Angeles, CA, USA)

12:20AM-12:40PM             Retrosigmoid approach for NF2 vestibular schwannoma
                                            Amir Samii, MD ( International Neuroscience Institute, Hannover, Germany)

12:40PM-1:00PM               NF-2 Spinal Tumor
                                            Gregory Lekovic, MD, PhD (House Ear Institute, Los Angeles, CA, USA)

1:00PM - 2:00PM               Lunch

2:00PM – 3:40PM: Session 3 - Roundtable discussion of selected clinical cases
Moderators: M. Kalamarides and G.  Lekovic

3:40PM – 5:40PM Session 4 - NF2 tumor management: towards the end of the preconceived ideas (Part 2)
Chairmen: D. Brackmann and John Golfinos

3:40PM – 4:00PM               Managing the facial nerve: role of decompression, radiosurgery and facial reanimation
                                            Rick Friedman, MD, PhD (House Ear Institute, Los Angeles, CA, USA)

4:00PM – 4:20PM               Lower cranial nerve tumor management in NF2
                                             Manuel Ferreira MD (University of Washington, St. Louis, MO, USA)

4:20PM-4:40PM                  Coffee Break

4:40PM - 5:00PM                Peripheral nerve tumor surgery
                                             Allan Belzberg, MD (Johns Hopkins University, Baltimore, MD)

5:00PM - 5:20PM                The Guy’s NF2 Impact Severity Score (NFTI-SS) - Platform Abstract Presentation
                                             Rachael Hornigold, MSc MBBS MRCS (Guy’s and St Thomas’ NHS Trust, London, UK)

7:00PM - 9:00PM                Social Dinner and Award Ceremony (Career Award to W. Hitselberger)

Tuesday, May 4, 2010

8:00AM – 12:00PM - Session 5 - Auditory rehabilitation
Chairmen: R. Shannon and V. Colletti

8:00AM-8:20AM                  Auditory brainstem implant : past, present, future
                                             Robert Shannon PhD (House Ear Institute, Los Angeles, CA, USA)

8:20AM-8:35AM                  ABI implantation: anatomical factors and surgical technique
                                             William Hitselberger, MD (Life-time Career Award Honoree)

8:35AM-09:20AM               ABI implantation: anatomical factors and surgical technique
                                             Jose Fayad  MD (House Ear Institute, Los Angeles, CA, USA)                               
                                             Marc Schwartz, MD (House Ear Institute, Los Angeles, CA, USA)
                                             Robert Behr MD (Klinikum-Fulda, Fulda, Germany)

9:20AM-09:40AM               Non NF2-ABI indications
                                             Olivier Sterkers MD (Beaujon Hospital, Clichy, France)

9:40AM-10:00AM               ABI in Children
                                            Lialiana Colletti MD (University of Verona, Verona, Italy)

10:00AM-10:15AM             Coffee Break

10:15AM-11:50AM   Auditory brainstem implant : past, present, future
Steven Otto (HEI, Los Angeles, USA) and R. Behr (Klinikum-Fulda, Germany)

10:15AM-10:35AM             The Penetrating-electrode Auditory Brainstem Implant (PABI)
                                             Eric Wilkinson MD (House Ear Institute, Los Angeles, CA, USA)

10:35AM-10:55AM             Cochlear implants in NF2: indications and results
                                             Pamela Roehm,  MD, Ph.D. (New York University, New York, NY, USA)

10:55AM-11:15AM             Digisonic ABI experience: long term results
                                            Christophe Vincent  MD (Lille, France)

11:15AM-11:35AM             CIs vs ABIs: the role of intraoperative monitoring
                                            Vittorio Colletti (University of Verona, Verona, Italy)
    

11:35AM -12:10PM: Session 6 – NF2 tumor management: towards the end of the preconceived ideas (Part 3)
Chairmen: D. Brackmann and A. Samii

11:35AM – 11:55PM          Radiosurgery for Schwannoma
                                            John Adler, MD (Standford University, Palo Alto, CA, USA)

11:55PM – 12:10PM          Fractionated Stereotactic Radiotherapy (FSR) for vestibular schwannoma
                                            Randall Porter MD (Barrow Neurological Institute, Phoenix, AZ)

12:10PM - 1:30PM             Lunch

1:30PM -4:50PM - Session 7 - Future frontiers for NF2 management
Chairmen: G. Evans and M. Giovannini

1:30PM - 1:50PM                Genetic testing for NF2 and schwannomatosis
                                             Ludwine Messiaen PhD (University of Alabama, Birmingham, AL, USA)

1:50PM - 2:05PM                Coordinated care for people with Neurofibromatosis type two (NF2): the English model - Platform Abstract Presentation
                                             Sue Huson MD, FRCP (University of Manchester, UK)

2:05PM - 2:25PM                Three-dimensional volumetrics for tracking vestibular, spinal and peripheral schwannoma growth
                                             in NF2 Defining endpoints  for clinical trials
                                             Gordon Harris PhD (Massachusetts General Hospital, Boston, MA, USA)

2:25PM - 2:45PM                 Building a NF2 Clinical Trial Pipeline: Introduction
                                              Kim Hunter-Schaedle PhD (Children Tumor Foundation, New York, NY, USA)

2:45PM - 3:05PM                Preclinical drug testing in NF2
                                             Marco Giovannini MD, PhD (House Ear Institute, Los Angeles, CA)

3:05PM - 3:25PM                NF2 Phase II PTC-299 Trial: Progress and Challenges
                                             Harry Miao MD (PTC Therapeutics, Inc. South Plainfield, NJ, USA)

3:25PM - 3:45PM                Coffee Break

3:45PM - 4:05PM                NF2 Phase 0 Lapatinib Trial: Progress and Challenges
                                             Jaishri Blakeley, MD (Johns Hopkins University, Baltimore, MD, USA)

4:05PM - 4:25PM                NF2 Phase II Bevacizumab Trial: Progress and Challenges
                                             Scott R. Plotkin, MD, Ph.D. (Massachusetts General Hospitall, Boston, MA, USA)

4:25PM-  4:45PM               Targeting a chaperone for neurofibromatosis type 2
                                            Ruihong Chen, Ph.D. (NexGenix Pharmaceuticals)

4:45PM - 5:05PM               Testing NIBs and alike in vitro: Which is the best to treat schwannomas? - Platform Abstract Presentation
                                            C. Oliver Hanemann MD, PhD, FRCP (Peninsula Medical School, United Kingdom)

5:05PM -  5:15PM              Honokiol, a natural plant product, inhibits the growth of vestibular schwannoma cells - Platform Abstract Presentation
                                           Jong Dae Lee MD (Soonchunhyang University College of Medicine, South Korea)

5:15PM - 5:25PM               General Discussion and Conclusions